BACKGROUND: Multimorbidity (defined as ≥2 chronic conditions) has been associated with increased risk of mild cognitive impairment and cross-sectionally with imaging biomarkers of neurodegeneration in cognitively unimpaired persons aged ≥70 years. Its association with preclinical Alzheimer's disease stages has not been studied in detail yet. The objective of the study was to assess the cross-sectional association of multimorbidity with preclinical Alzheimer's disease stages and suspected non-amyloid pathophysiology in cognitively unimpaired participants of the Mayo Clinic Study of Aging (≥50 years of age). METHODS: The study included 1,535 cognitively unimpaired participants with multimorbidity, 11C-PiB positron emission topography and magnetic resonance imaging data available. Abnormal (elevated) 11C-PiB-positron emission topography retention ratio (A+; standardized uptake value ratio >1.42) and abnormal (reduced) Alzheimer's disease signature cortical thickness (N+; <2.67 mm) were used to define biomarker combinations (A-N-, A+N-, A-N+, A+N+). Chronic medical conditions were ascertained by using the Rochester Epidemiology Project medical records linkage system and International Classification of Diseases criteria. Cross-sectional associations were examined using multinomial logistic regression models adjusting for age, sex, education, and apolipoprotein E ɛ4 allele status. RESULTS: Frequency of A+, N+, A+N+, and A-N+ biomarker groups increased significantly with increasing number of chronic conditions. Multimorbidity was significantly associated with A+N+ (vs A-N-; odds ratio, 1.76, 95% confidence interval 1.02, 2.90) and A-N+ (vs A-N-; odds ratio, 2.16, 95% confidence interval 1.47, 3.18). There was a dose-response relationship between increasing number of chronic conditions (eg, 0-1, 2-3, and 4+) and the odds of A+N+ and A-N+ (vs A-N-). CONCLUSIONS: Multimorbidity was associated with biomarker combinations that included neurodegeneration with or without elevated amyloid deposition (ie, A-N+, A+N+). The associations should be validated in longitudinal studies.
BACKGROUND: Multimorbidity (defined as ≥2 chronic conditions) has been associated with increased risk of mild cognitive impairment and cross-sectionally with imaging biomarkers of neurodegeneration in cognitively unimpaired persons aged ≥70 years. Its association with preclinical Alzheimer's disease stages has not been studied in detail yet. The objective of the study was to assess the cross-sectional association of multimorbidity with preclinical Alzheimer's disease stages and suspected non-amyloid pathophysiology in cognitively unimpaired participants of the Mayo Clinic Study of Aging (≥50 years of age). METHODS: The study included 1,535 cognitively unimpaired participants with multimorbidity, 11C-PiB positron emission topography and magnetic resonance imaging data available. Abnormal (elevated) 11C-PiB-positron emission topography retention ratio (A+; standardized uptake value ratio >1.42) and abnormal (reduced) Alzheimer's disease signature cortical thickness (N+; <2.67 mm) were used to define biomarker combinations (A-N-, A+N-, A-N+, A+N+). Chronic medical conditions were ascertained by using the Rochester Epidemiology Project medical records linkage system and International Classification of Diseases criteria. Cross-sectional associations were examined using multinomial logistic regression models adjusting for age, sex, education, and apolipoprotein E ɛ4 allele status. RESULTS: Frequency of A+, N+, A+N+, and A-N+ biomarker groups increased significantly with increasing number of chronic conditions. Multimorbidity was significantly associated with A+N+ (vs A-N-; odds ratio, 1.76, 95% confidence interval 1.02, 2.90) and A-N+ (vs A-N-; odds ratio, 2.16, 95% confidence interval 1.47, 3.18). There was a dose-response relationship between increasing number of chronic conditions (eg, 0-1, 2-3, and 4+) and the odds of A+N+ and A-N+ (vs A-N-). CONCLUSIONS: Multimorbidity was associated with biomarker combinations that included neurodegeneration with or without elevated amyloid deposition (ie, A-N+, A+N+). The associations should be validated in longitudinal studies.
Authors: Anouk G W van Norden; Ewoud J van Dijk; Karlijn F de Laat; Philip Scheltens; Marcel G M Olderikkert; F E de Leeuw Journal: Biochim Biophys Acta Date: 2011-07-14
Authors: Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Walter A Rocca Journal: Am J Epidemiol Date: 2011-03-23 Impact factor: 4.897
Authors: Elisa Fabbri; Yang An; Marco Zoli; Toshiko Tanaka; Eleanor M Simonsick; Melissa H Kitner-Triolo; Stephanie A Studenski; Susan M Resnick; Luigi Ferrucci Journal: J Am Geriatr Soc Date: 2016-04-30 Impact factor: 5.562
Authors: Walter A Rocca; Cynthia M Boyd; Brandon R Grossardt; William V Bobo; Lila J Finney Rutten; Véronique L Roger; Jon O Ebbert; Terry M Therneau; Barbara P Yawn; Jennifer L St Sauver Journal: Mayo Clin Proc Date: 2014-09-11 Impact factor: 7.616
Authors: Clifford R Jack; Val J Lowe; Matthew L Senjem; Stephen D Weigand; Bradley J Kemp; Maria M Shiung; David S Knopman; Bradley F Boeve; William E Klunk; Chester A Mathis; Ronald C Petersen Journal: Brain Date: 2008-02-07 Impact factor: 13.501
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Neuroepidemiology Date: 2008-02-07 Impact factor: 3.282
Authors: Davide L Vetrano; Amaia Calderón-Larrañaga; Alessandra Marengoni; Graziano Onder; Jürgen M Bauer; Matteo Cesari; Luigi Ferrucci; Laura Fratiglioni Journal: J Gerontol A Biol Sci Med Sci Date: 2018-09-11 Impact factor: 6.053
Authors: Peter T Nelson; Dennis W Dickson; John Q Trojanowski; Clifford R Jack; Patricia A Boyle; Konstantinos Arfanakis; Rosa Rademakers; Irina Alafuzoff; Johannes Attems; Carol Brayne; Ian T S Coyle-Gilchrist; Helena C Chui; David W Fardo; Margaret E Flanagan; Glenda Halliday; Suvi R K Hokkanen; Sally Hunter; Gregory A Jicha; Yuriko Katsumata; Claudia H Kawas; C Dirk Keene; Gabor G Kovacs; Walter A Kukull; Allan I Levey; Nazanin Makkinejad; Thomas J Montine; Shigeo Murayama; Melissa E Murray; Sukriti Nag; Robert A Rissman; William W Seeley; Reisa A Sperling; Charles L White; Lei Yu; Julie A Schneider Journal: Brain Date: 2019-06-01 Impact factor: 15.255
Authors: Lianlian Du; Rebecca Langhough Koscik; Nathaniel A Chin; Lisa C Bratzke; Karly Cody; Claire M Erickson; Erin Jonaitis; Kimberly D Mueller; Bruce P Hermann; Sterling C Johnson Journal: Front Aging Date: 2022-01-03
Authors: Alex C Birdsill; Rebecca L Koscik; Karly A Cody; Erin M Jonaitis; Robert V Cadman; Claire M Erickson; Nathaniel A Chin; Robert J Przybelski; Cynthia M Carlsson; Sanjay Asthana; Bradley T Christian; Laura B Eisenmenger; Tobey J Betthauser; Sterling C Johnson Journal: Alzheimers Dement (Amst) Date: 2022-09-20